- Home
- BYSI vs IVVD Comparison
BYSI vs IVVD Comparison
Compare BYSI & IVVD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BYSI
- IVVD
- Stock Information
- Founded
- BYSI 2010
- IVVD 2020
- Country
- BYSI United States
- IVVD United States
- Employees
- BYSI N/A
- IVVD N/A
- Industry
- BYSI Biotechnology: Pharmaceutical Preparations
- IVVD Biotechnology: Pharmaceutical Preparations
- Sector
- BYSI Health Care
- IVVD Health Care
- Exchange
- BYSI Nasdaq
- IVVD Nasdaq
- Market Cap
- BYSI 69.3M
- IVVD 66.6M
- IPO Year
- BYSI 2017
- IVVD 2021
- Fundamental
- Price
- BYSI $1.72
- IVVD $0.41
- Analyst Decision
- BYSI
- IVVD Strong Buy
- Analyst Count
- BYSI 0
- IVVD 4
- Target Price
- BYSI N/A
- IVVD $7.89
- AVG Volume (30 Days)
- BYSI 21.8K
- IVVD 1.9M
- Earning Date
- BYSI 01-01-0001
- IVVD 11-14-2024
- Dividend Yield
- BYSI N/A
- IVVD N/A
- EPS Growth
- BYSI N/A
- IVVD N/A
- EPS
- BYSI N/A
- IVVD N/A
- Revenue
- BYSI $1,876,000.00
- IVVD $11,564,000.00
- Revenue This Year
- BYSI N/A
- IVVD N/A
- Revenue Next Year
- BYSI N/A
- IVVD $486.65
- P/E Ratio
- BYSI N/A
- IVVD N/A
- Revenue Growth
- BYSI 21.03
- IVVD N/A
- 52 Week Low
- BYSI $0.82
- IVVD $0.38
- 52 Week High
- BYSI $4.00
- IVVD $5.20
- Technical
- Relative Strength Index (RSI)
- BYSI 52.47
- IVVD 38.26
- Support Level
- BYSI $1.58
- IVVD $0.38
- Resistance Level
- BYSI $1.75
- IVVD $0.50
- Average True Range (ATR)
- BYSI 0.09
- IVVD 0.07
- MACD
- BYSI 0.02
- IVVD 0.00
- Stochastic Oscillator
- BYSI 74.07
- IVVD 11.73
About BYSI BeyondSpring Inc.
BeyondSpring Inc is engaged in clinical-stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. It has two reportable segments Plinabulin pipeline and the TPD platform.
About IVVD Invivyd Inc.
Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.